Concepedia

Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study

Zhiyong Zeng, Apeng Yang, Jingke Yang, Sheng Zhang, Zhen Xing, Xingfu Wang, Wenzhong Mei, Changzhen Jiang, Jun‐Fang Lin, Xiyue Wu,

Signal Transduction and Targeted Therapy · 2024 · 16 citations · 31 references

DOIFull text

Open access

References

31

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.8K citations · Full text

Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

Lauren E. Abrey, Tracy T. Batchelor, Andrés J.M. Ferreri et al. · Journal of Clinical Oncology · 2005 · 882 citations

, , +17

Targetable genetic features of primary testicular and primary central nervous system lymphomas

Bjoern Chapuy, Margaretha G.M. Roemer, Chip Stewart et al. · Blood · 2015 · 590 citations · Full text

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2016 · 582 citations · Full text

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Jason R. Westin, Fuliang Chu, Min Zhang et al. · The Lancet Oncology · 2013 · 528 citations · Full text

, , +10